XNYS
ZTS
Market cap30bUSD
Oct 08, Last price
73.08USD
1D
2.14%
1Q
-3.28%
Jan 2017
36.52%
IPO
135.59%
Name
Zoetis Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zoetis Inc. is a global enterprise dedicated to the research, development, production, and marketing of a broad spectrum of animal health products. Operating both within the United States and globally, the company primarily serves a diverse range of animals, including major livestock categories such as cattle, swine, poultry, fish, and sheep, alongside companion animals like dogs, cats, and horses. Their extensive portfolio features various solutions, including biological vaccines engineered to prevent ailments of the respiratory, gastrointestinal, and reproductive systems, or to stimulate targeted immune responses. They also provide anti-infectives designed to combat bacterial, fungal, or protozoal pathogens, and parasiticides effective against both internal (e.g., worms) and external (e.g., fleas, ticks) parasites. Beyond these, Zoetis offers a suite of other pharmaceutical products, spanning pain management, sedation, antiemetics, reproductive aids, and oncology treatments. Their offerings also include dermatological solutions for allergic skin conditions and atopic dermatitis, as well as medicated feed additives specifically for livestock. The company further innovates in diagnostic tools, offering portable blood and urine analysis systems, point-of-care devices, instruments, reagents, rapid immunoassay tests, reference laboratory services, and blood glucose monitors. Non-pharmaceutical lines extend to nutritional supplements, agribusiness support, biodevices, genetic testing, and precision animal health technologies. Zoetis reaches its customer base, which comprises veterinarians, livestock producers, and retail outlets, through its own sales representatives and specialized technical and veterinary operations personnel, as well as via third-party veterinary distributors. Founded in 1952, the firm maintains its headquarters in Parsippany, New Jersey.
Related entities
Subsidiaries (12)
PHARMAQ AS
PHARMAQ VIETNAM CO., LTD
ZOETIS BELGIUM
ZOETIS BIOPHARMACEUTICAL CO., LTD.
Zoetis Ceska republika, s.r.o.
Zoetis India Capability Center Private Limited
ZOETIS KOREA LTD
ZOETIS PHARMACEUTICAL RESEARCH PRIVATE LIMITED
ZOETIS PHILIPPINES, INC.
ZOETIS SINGAPORE PTE. LTD.
ZOETIS TREASURY CENTER
ZOETIS VIETNAM CO., LTD
Key people
Non-Executive Independent Chairman of the Board · since 2015
Glenn C. David
Chief Financial Officer, Executive Vice President · since 2016
Catherine A. Knupp
Executive Vice President, President - Research and Development · since 2012
Roman Trawicki
Executive Vice President, President - Global Manufacturing and Supply · since 2015
Heidi C. Chen
Executive Vice President, General Counsel, Corporate Secretary · since 2012
Independent Director · since 2015
Independent Director · since 2016
Sanjay Khosla
Independent Director · since 2013
Independent Director · since 2013
Louise M. Parent
Independent Director · since 2013
Willie M. Reed
Independent Director · since 2014
Linda Rhodes
Independent Director · since 2017
Independent Director · since 2013
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
10 Sylvan Way
Parsippany-Troy Hills, NJ 07054
US
Parsippany-Troy Hills, NJ 07054
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||